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Abstract
Background—Descriptive epidemiologic studies of recurrent and non-recurrent Kawasaki 
disease (KD) may identify other potentially important differences between these illnesses.
Methods—Data from the United States and Japan, the Centers for Disease Control and 
Prevention (CDC) national KD surveillance (1984–2008) and the 17th Japanese nationwide survey 
(2001–2002), respectively, were analyzed to examine recurrent KD patients <18 years of age 
meeting the CDC KD case or atypical KD case definition. These patients were compared to non-
recurrent KD patients.
Results—Of the 5557 US KD patients <18 years of age during 1984–2008, 97 (1.7%) were 
identified as having had recurrent KD. Among the US Asian/Pacific Islander KD patients, 3.5% 
had recurrent KD, which was similar to the percentage identified among KD patients (3.5%) in the 
Japanese survey. Compared to non-recurrent KD patients, KD patients experiencing a recurrent 
KD episode were more likely to be older, fulfill the atypical KD case definition, and have 
coronary artery abnormalities (CAA) despite IVIG treatment.
Conclusions—Differences in the age, race, and frequency of CAA exist between recurrent and 
non-recurrent KD patients. The increased association of CAA with recurrent KD suggests that 
more aggressive treatment strategies in conjunction with IVIG may be indicated for the second 
episode of KD.
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Kawasaki disease (KD) is an acute febrile vasculitis of unknown etiology that occurs 
worldwide.1–7 KD primarily affects young children, with the majority of KD cases being <5 
years of age, and it is more common in males and among children of Asian descent.1–4,7–14 
Japan has reported the highest incidence of KD, with 239.6 cases per 100,000 children <5 
years of age reported for 2010.7 In the United States (US), studies have shown incidence and 
hospitalization rates to range from approximately 9–21 cases per 100,000 children <5 years 
of age.1, 3, 9, 11 In Hawaii, where a large proportion of children are of Asian descent, KD 
incidence has been reported to be 50.4 per 100,000 children <5 years of age, with an 
incidence of 210.5 for those of Japanese ancestry.15
KD causes significant morbidity in most patients and may result in cardiac and non-cardiac 
complications, the most serious of which are coronary artery abnormalities (CAAs).1–4, 7–9 
Treatment with intravenous immunoglobulin (IVIG) and aspirin is generally effective in 
reducing the occurrence of CAAs, and current recommendations in the United States specify 
that IVIG should be administered as soon as possible after illness onset.2, 4 While no 
specific agent has been identified, features of KD appear to be consistent with an infectious 
etiology.1, 2, 4, 16, 17 The lack of a diagnostic test for KD means that diagnosis is dependent 
upon an assessment of the presence of specific disease criteria using a case definition. 
Because IVIG therapy is believed to be more effective when administered early, physicians 
may choose to diagnose a patient with KD and begin treatment even if the KD case 
definition is not fulfilled.4, 18, 19
Previous studies in the United States and Japan have determined KD to recur in ~2–4% of 
patients.2, 4, 7, 14, 16, 17, 20, 21 A study of KD patients in China reported that children with 
recurrent KD were more likely to present with incomplete clinical signs,22 while Japanese 
studies have suggested that patients with recurrent KD may present with a more serious 
illness than the initial episode.21. 23 Other Japanese studies have reported that recurrence is 
more common among children who were <3 years of age at the initial episode.17, 20 In the 
United States, studies of recurrent KD have typically focused on a very small number of 
cases or have been limited to a single institution.24 The present study includes the first in-
depth analyses of KD recurrence using national Centers for Disease Control and Prevention 
(CDC) surveillance data. It also includes the first analyses of KD recurrence using CDC 
clinical KD case definitions applied to national KD survey data from Japan.
The goal of this study was to describe the epidemiology of recurrent KD among children in 
the United States and in Japan, and compare the KD patients with recurrence with non-
recurrent KD patients by demographic factors, timing of treatment, and the occurrence of 
CAAs. Determining risk factors for KD recurrence may assist the treating physician, 
especially if earlier or more aggressive treatment for these cases is warranted.
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Since 1976, CDC has conducted passive national surveillance for KD using a standardized 
KD case report form.2, 8 Information from these forms has been entered into an electronic 
database beginning in 1984. The case report form has been periodically revised, most 
recently in 2004, and collects information on KD patient demographics, clinical signs, 
treatment, and complications.25 In 1991, a separate question was added to the form to 
ascertain whether the KD case was recurrent and, if so, the onset date of the previous 
episode. Earlier versions of the form included recurrence as a possible response to disease 
outcome. In both scenarios, the classification of a KD case as recurrent has been dependent 
on the physician’s assessment.
Records for children <18 years of age meeting the CDC epidemiologic case definition for 
KD or atypical KD with onset during 1984–2008 were selected for analysis.2, 8 The CDC 
KD case definition requires that a patient has fever for ≥5 days (or fever until IVIG 
administration if given before the fifth day of fever) and the presence of at least 4 of the 
following 5 clinical signs: bilateral conjunctival injection, oral mucosal changes, peripheral 
extremity changes, rash, and cervical lymphadenopathy (at least 1.5 cm in diameter).2, 8 
Patients not meeting the KD case definition, but with fever of any duration and CAAs, are 
classified as having atypical KD.2, 9 CAA is defined as the presence of coronary artery 
dilatation or aneurysm. When available, original hardcopies of report forms for recurrent 
cases were reviewed to ascertain the presence of KD recurrence. In instances where 
additional information on the form suggested that the recurrent admission was a 
continuation of the initial episode and not a true recurrence, the patient information was 
recoded as non-recurrent. Attempts were made to locate information in the database for the 
initial KD episode of each recurrent KD case; however, unless stated otherwise, analyses of 
recurrent KD cases used data obtained from the recurrent KD episode for comparison to 
non-recurrent KD cases.
Japan data
Nationwide surveys for KD have been conducted every two years since 1970.6, 7, 12–14, 17, 26 
Pediatricians from all pediatric hospitals and all other general hospitals with a pediatric 
department and ≥100 beds in Japan are asked to complete a questionnaire for each KD case 
they diagnose during the specified time period.6, 7, 12–14, 17, 26 Questionnaires vary from 
survey to survey, but they typically include questions about demographics, treatment, 
complications, and recurrence. Data from the 17th Japanese national KD survey, covering 
the years 2001–2002, were obtained and translated to English by Dr. Ritei Uehara. This 
survey was sent to 2413 hospitals in Japan, with 68% responding.26 The 17th survey is 
unique among the Japanese KD surveys in that information on KD clinical criteria was 
collected, allowing for analyses using the CDC KD case definition, which varies slightly 
from the Japanese KD case definition.26 The Japanese KD definition does not require the 
presence of fever, but includes it as 1 of 6 criteria along with the 5 CDC KD criteria 
mentioned previously. Cases meeting 5 or 6 criteria are considered complete cases; those 
with 4 criteria and CAAs are classified as incomplete KD.26 While the US KD definition 
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specifies a size (≥1.5 cm) for cervical lymphadenopathy, the Japanese definition does not; 
size information was not available in the Japanese survey, so patients recorded as having 
cervical lymphadenopathy in the Japanese data were classified as meeting this criterion for 
the purposes of applying the US CDC KD case definition. KD cases in the Japanese survey 
are classified as recurrent if there is an interval of at least two months from the onset of the 
first KD illness to onset of the new episode.17
Statistical Analysis
The Wilcoxon rank-sum test was used for comparison of continuous variables such as 
patient age. The Chi-square test and Fisher’s exact test (two-sided) were used, as 
appropriate, to compare categorical variables including the presence of clinical criteria, 
treatment with IVIG before the fifth day of illness, and the occurrence of CAAs. Risk ratios 
(RRs) with 95% confidence intervals (CIs) were calculated to compare KD recurrence by 
race and ethnicity. Statistical analyses were performed using SAS version 9.2 (SAS institute, 
Cary, NC). A p-value <0.05 was considered as the significance level.
Results
United States
There were 9636 KD patients <18 years of age reported to the US CDC KD surveillance 
program with onset during 1984–2008, with 6195 (64.3%) having recurrence data available. 
A majority (97.8%) of these 6195 patients had KD onset after 1990. Of the 6195 patients, 
5339 (86.2%) met the CDC KD case definition, 218 (3.5%) met the atypical KD case 
definition, and 638 (10.3%) did not meet either case definition. The 5557 patients with 
recurrence data meeting either the CDC KD case definition or atypical KD case definition 
resided in 48 states and the District of Columbia, with 43.1% of the patients living in 
California. KD recurrence was indicated for 97 of the 5557 patients (1.7%), with a 
significantly higher percentage of recurrent cases being found among atypical KD patients 
compared to those meeting the CDC KD case definition (9 of 218 (4.1%) and 88 of 5339 
(1.6%) patients, respectively) (p=0.006). Eleven of the 638 (1.7%) KD patients not meeting 
the CDC KD case definition or atypical KD case definition were recurrent; this proportion 
was not significantly different to the proportion of recurrence among KD patients meeting 
the CDC KD case definition or atypical KD case definition.
The annual percentage of recurrent cases among patients meeting the CDC KD case 
definition and atypical KD case definition was relatively stable, ranging from 0.4%–2.7% 
during the 1991–2008 period when most recurrence data were available. The percentages of 
recurrent KD cases among male and female KD patients (1.9% and 1.3%, respectively) were 
not significantly different (p=0.07). The 48 recurrent KD patients for whom age information 
was available for the initial KD episode had a median age of 21.5 months (mean 26.1, range 
3–68 months), which was significantly younger than non-recurrent KD patients, who had a 
median age of 31 months (mean 39.1 months, range 0–214 months) (p=0.004). Recurrent 
KD patients at their recurrent KD episode, with a median age of 43 months (mean 47 
months, range 3–148 months), were significantly older than the non-recurrent KD patients 
(p=0.002). For 48 recurrent KD patients with information available on the time between KD 
Maddox et al. Page 4













episodes, the median duration was 17 months (mean 22.5 months, range 2–140 months). No 
recurrent KD patients were reported to have died; three deaths (0.05%) were reported among 
non-recurrent KD patients. For KD patients meeting the CDC KD case definition (atypical 
KD cases excluded), there were no significant differences in the presence of clinical criteria 
for recurrent and non-recurrent cases (Table 1).
For recurrent KD patients with treatment information available, most (71 of 74, 96.0%) 
received IVIG; if given IVIG, recurrent KD patients were more likely to receive treatment 
before the 5th day of illness compared to non-recurrent KD patients (44.6% vs. 29.9%, 
p=0.01). Of the 79 recurrent patients meeting the CDC KD case definition who had CAA 
information available, 19 (24.1%) had CAAs, which was significantly more than the 14.3% 
of non-recurrent KD patients with CAAs (p=0.01) (Table 1). All recurrent patients meeting 
the CDC KD case definition with CAAs with treatment information available (n=14) 
received IVIG; 45.5% (5 of 11) received treatment within 5 days of onset. Among recurrent 
KD patients with atypical KD, who by definition had CAAs, 5 of 8 (62.5%) received IVIG, 
and 33.3% (1 of 3) received the treatment within 5 days.
Previous admission data were available for 11 recurrent KD patients (Table 2). Ten of 11 
(90.9%) met the CDC KD case definition on their initial KD episode. Eight of these 10 
(80.0%) met the CDC KD case definition on their recurrent KD episode; the remaining 2 
met criteria for atypical KD. Three of 10 (30.0%) patients with CAA information available 
had CAAs on their initial KD episode.
The proportion of Asian US KD patients that were recurrent was higher compared to that for 
white KD patients (3.5% and 1.5%, respectively; RR 2.3, 95% CI 1.4, 3.7) (Table 3). There 
was no difference in the percentage of recurrent KD patients between Asian male and Asian 
female KD patients (4.1% and 2.6%, respectively, p=0.26). The median age for Asian 
recurrent KD patients was 47 months (mean 47.2 months, range 5–141 months), which was 
similar to the median age of 43 months for white recurrent KD patients and significantly 
older than the median age of 28 months (mean 33.5, range 1–188) for Asian non-recurrent 
cases (p<0.001). All Asian recurrent KD patients with treatment information available 
(n=28) received IVIG; Asian recurrent KD patients were more likely to receive treatment 
before the 5th day of illness compared to non-recurrent Asian KD patients who received 
treatment (p=0.01). Of the 25 Asian recurrent KD patients meeting the CDC KD case 
definition and with CAA information available, 5 (20.0%) had CAAs, which was not 
significantly different compared to the 18.6% of Asian non-recurrent KD patients with 
CAAs (p=0.86). Four of the 5 patients had information reported about the start of treatment; 
all 4 received IVIG within 5 days.
Japan
There were 16949 physician-diagnosed KD patients <18 years of age with recurrence data 
available reported in the 17th national KD survey. Of these, 13240 (78.1%) met the CDC 
KD case definition, 634 (3.7%) met the atypical KD definition, and 3075 (18.1%) did not 
meet either definition. Of the 13874 patients meeting the CDC KD case definition or 
atypical KD case definition, 483 (3.5%) were recorded as having recurrent KD; a 
significantly higher percentage of recurrent cases were found among atypical KD patients 
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compared to those meeting the CDC KD case definition (34 of 634 (5.4%) and 449 of 13240 
(3.4%) patients, respectively) (p=0.01). There was no difference in the percentage of 
recurrent cases between male and female patients (3.6% and 3.3%, respectively, p=0.38). 
Fewer recurrent KD patients meeting the US CDC KD case definition (atypical KD cases 
excluded) had rash compared to non-recurrent KD patients, while more recurrent KD 
patients had cervical lymphadenopathy (Table 1). The median age for recurrent KD patients 
was 42 months (mean 45.8 months, range 3.9–189.0 months), significantly higher than the 
24.1 months for non-recurrent patients (mean 30.4 months, range 0.3–212.6 months) 
(p<0.0001). Most recurrent KD patients (447 of 483, 92.6%) received IVIG; if given IVIG, 
recurrent KD patients were not significantly more likely to receive treatment before the 5th 
day of illness compared to non-recurrent KD patients (p=0.07). Of recurrent KD patients 
meeting the CDC KD case definition with CAA information available, 86 of 449 (19.2%) 
had CAAs, significantly more than the 1802 of 12791 (14.1%) non-recurrent KD patients 
with CAAs (p=0.003). Almost all recurrent KD patients meeting the CDC KD case 
definition with CAAs had IVIG treatment (85/86, 98.8%); 37.8% (31 of 82) received 
treatment within 5 days. Among recurrent KD patients with atypical KD and CAAs, 29 of 
34 (85.3%) received IVIG, and 21.4% (6 of 28) received the treatment within 5 days.
Discussion
Consistent with previous studies, KD recurrence was reported in a small percentage of KD 
cases.2, 4, 7, 14, 16, 17, 20, 21 Patients with recurrent KD tended to be older than KD patients 
without recurrence, which was expected given that they had experienced a previous episode 
of KD. Asian children in the United States were at increased risk of KD recurrence 
compared to white KD patients. Despite the heterogeneity of the Asian race classification in 
the United States, which includes various Asian populations as well as Pacific Islanders, 
recurrence among Asian children with KD (3.5%) was remarkably similar to recurrence 
among Japanese children with KD in Japan (3.5%). In the United States and Japan, recurrent 
KD patients overall were more likely to have CAAs compared to non-recurrent KD patients; 
for US Asian KD patients alone, a significant difference was not found, which could be 
influenced by the smaller numbers available for analysis.
The difference in CAA occurrence between recurrent and non-recurrent US KD cases is 
particularly notable because recurrent KD patients, possibly resulting from increased 
suspicion of KD by doctors aware of a previous KD episode, were more likely to receive 
IVIG before the fifth day of illness. While only 11 patients in the US CDC database had 
matched information for initial and recurrent KD episodes, the following findings from these 
episodes were consistent with previous studies:17, 21 CAAs were more commonly reported 
in recurrent cases that also had CAA at the initial episode, most patients were <3 years of 
age at their initial episode, and the majority of patients had recurrence within two years of 
their initial episode.
Limitations of the study included the inability to verify KD recurrence for many reported 
recurrent KD patients in the US CDC database. Dates of the initial KD episode were not 
available for 53% of the US recurrent KD patients, and it is possible that some patients may 
have been classified as recurrent when they were actually experiencing a continuation of the 
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initial episode. Conversely, some recurrent KD patients may not have been identified as 
recurrent if the person completing the form was not aware of the previous KD episode or if 
the initial or recurrent illness had an atypical presentation. The US CDC database has 
limited availability of recurrence data prior to 1991, and the CDC KD surveillance system is 
passive.2 Some states and medical centers do not report or fully report KD cases, while other 
states, notably California, are more represented in the database. For the Japanese national 
database, it has been reported that the majority of KD patients are identified through the 
national KD surveys, with more than 90% of KD patients treated in surveyed hospitals.12
Further study of well-defined recurrent KD patients, particularly focusing on the initial KD 
episode, the treatment or treatments administered, and treatment response, is needed to 
better understand KD recurrence and to appropriately treat such patients. Despite the finding 
that US children with recurrent KD are more likely to be treated before the fifth day of 
illness, recurrent KD patients remain at increased risk of CAAs compared to non-recurrent 
KD cases. A study using Japanese data has also reported that IVIG nonresponse may be 
more likely when treating recurrent episodes of KD.6 These findings indicate that a different 
treatment strategy, such as inclusion of a more potent anti-inflammatory drug with the initial 
IVIG treatment, may be warranted in patients showing early signs of KD recurrence. 
Kobayashi et al. recently reported that the use of steroids was effective in reducing the 
occurrence of CAAs among severe KD patients in Japan.27
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Table 3
Recurrent Kawasaki disease (KD) patients <18 years of age by race and ethnicity, United States, 1984–2008*
Recurrent KD Non-recurrent KD Recurrence (%) RR, 95% CI
Race** n=90 n=4908
 White 46 (51.1%) 2926 (59.6%) 46/2972 (1.5%) Reference
 Black 12 (13.3%) 912 (18.6%) 12/924 (1.3%) 0.8 (0.4, 1.6)
 Asian/Pacific Islander 29 (32.2%) 807 (16.4%) 29/836 (3.5%) 2.3 (1.4, 3.7)
 American Indian/Alaska Native 0 (0.0%) 21 (0.4%) 0/21 (0.0%) ——
 Other 3 (3.3%) 242 (4.9%) 3/245 (1.2%) 0.8 (0.2, 2.6)
Ethnicity** n=52 n=4342
 Non-Hispanic 39 (75.0%) 3208 (73.9%) 39/3247 (1.2%) Reference
 Hispanic 13 (25.0%) 1134 (26.1%) 13/1147 (1.1%) 0.9 (0.5, 1.8)
*
RR=risk ratio, CI=confidence interval
**
10.1% of patients missing race information, 20.9% of patients missing ethnicity information
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